First American Trust FSB Grows Position in Johnson & Johnson (NYSE:JNJ)

First American Trust FSB lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,054 shares of the company’s stock after purchasing an additional 139 shares during the quarter. First American Trust FSB’s holdings in Johnson & Johnson were worth $1,170,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of JNJ. CCM Investment Group LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at about $8,336,000. Nuveen LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at about $1,369,188,000. Scissortail Wealth Management LLC boosted its holdings in Johnson & Johnson by 37.2% during the 1st quarter. Scissortail Wealth Management LLC now owns 29,813 shares of the company’s stock valued at $4,944,000 after acquiring an additional 8,087 shares during the period. Cooper Financial Group boosted its holdings in Johnson & Johnson by 10.2% during the 1st quarter. Cooper Financial Group now owns 11,516 shares of the company’s stock valued at $1,910,000 after acquiring an additional 1,067 shares during the period. Finally, American Alpha Advisors LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at about $465,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on JNJ shares. Guggenheim restated a “neutral” rating and set a $167.00 target price (up from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Raymond James Financial lowered their target price on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a report on Monday, April 14th. Wall Street Zen cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, July 18th. Royal Bank Of Canada increased their price target on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. Finally, Leerink Partnrs lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Nine research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $174.50.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $173.40 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $173.96. The firm has a market capitalization of $417.61 billion, a PE ratio of 18.55, a price-to-earnings-growth ratio of 2.21 and a beta of 0.41. The stock’s 50-day simple moving average is $159.26 and its 200-day simple moving average is $157.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.82 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.